Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics) ...

GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, ...

Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — — The sentinel cohort is ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...

Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief ...

马萨诸塞州剑桥市 - mRNA疗法和疫苗领域的先驱Moderna Inc (NASDAQ:MRNA)今日宣布，前Vifor Pharma首席执行官和葛兰素史克制药和疫苗全球总裁Abbas Hussain已被任命为公司董事会成员。

Let the good times roll. The S&P 500 has soared nearly 21% in 2024, including a 2% gain in September. What's especially noteworthy is that the bull market has broadened to include more than only ...

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator ...

We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Moderna, ...

CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies ...